Navidea Biopharmaceuticals Inc (NYSE American:NAVB)

0.2995
Delayed Data
As of Apr 19
 +0.0034 / +1.15%
Today’s Change
0.29
Today|||52-Week Range
0.68
-16.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$62.4M

Company Description

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Contact Information

Navidea Biopharmaceuticals, Inc.
4995 Bradenton Avenue
Dublin Ohio 43017-3552
P:(614) 793-7500
Investor Relations:

Employees

Shareholders

Mutual fund holders4.53%
Individual stakeholders14.63%
Other institutional12.98%

Top Executives

Mike M. GoldbergPresident, Chief Executive Officer & Director
Jed Andrew LatkinCFO, COO, Secretary & Treasurer
Frederick O. CopeChief Scientific Officer & Senior Vice President
William J. ReganChief Compliance Officer & SVP-Global Regulatory